Date: 2015-05-20
Type of information: Private placement
Company: Auris Medical (Switzerland)
Investors:
Amount: $22.9 million
Funding type: private placement
Planned used: Auris Medicaly intends to use the net proceeds from the offering to fund research and development expenses for its Phase 3 AM-111 clinical program.
Others: * On May 20, 2015, Auris Medical announced public offering of 5,275,000 of its common shares at a public offering price of $4.75 per common share. In addition, Auris Medical granted the underwriters a 30-day option from May 14, 2015 to purchase up to 791,250 additional common shares at the public offering price, less underwriting discounts, to cover over-allotments. * On May 15, 2015, Auris Medical announced the pricing of its previously announced public offering of 5,275,000 of its common shares at a public offering price of $4.75 per common share. In addition, Auris Medical has granted the underwriters an option to purchase up to 791,250 additional common shares at the public offering price, less underwriting discounts, to cover over-allotments. After deducting the underwriting discounts and other estimated offering expenses, the net proceeds of the public offering are expected to be approximately $22.9 million. The offering is expected to close on or about May 20, 2015, subject to customary closing conditions.
* On May 4, 2015, Auris Medical announced that it is offering to sell 6,000,000 common shares in an underwritten public offering pursuant to a registration statement on Form F-1/A filed with the Securities and Exchange Commission. In connection with this offering, the Company expects to grant the underwriters a 30-day option to purchase up to an aggregate of 900,000 additional common shares to cover over-allotments. All of the shares are being offered by Auris Medical. There can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering. Leerink Partners LLC is acting as sole book-running manager, JMP Securities LLC and Needham & Company, LLC are acting as lead managers and LifeSci Capital LLC is acting as co-manager in the proposed offering.
Therapeutic area: Otorhinolaryngology
